In Parkinson disease (PD), mitochondrial dysfunction associates with nigral dopaminergic neuronal loss. Cholinergic neuronal loss co-occurs, particularly within a brainstem structure, the pedunculopontine nucleus (PPN). We isolated single cholinergic neurons from postmortem PPNs of aged controls and PD patients. Mitochondrial DNA (mtDNA) copy number and mtDNA deletions were increased significantly in PD patients compared to controls. Furthermore, compared to controls the PD patients had significantly more PPN cholinergic neurons containing mtDNA deletion levels exceeding 60%, a level associated with deleterious effects on oxidative phosphorylation. The current results differ from studies reporting mtDNA depletion in nigral dopaminergic neurons of PD patients. ANN NEUROL 2017;82:1016-1021 P arkinson disease (PD) patients typically present with tremor, bradykinesia, and rigidity, the onset and progression of which associate with selective loss of nigrostriatal dopaminergic neurons.
Ilse S. Pienaar, PhD 5, 6 In Parkinson disease (PD), mitochondrial dysfunction associates with nigral dopaminergic neuronal loss. Cholinergic neuronal loss co-occurs, particularly within a brainstem structure, the pedunculopontine nucleus (PPN). We isolated single cholinergic neurons from postmortem PPNs of aged controls and PD patients. Mitochondrial DNA (mtDNA) copy number and mtDNA deletions were increased significantly in PD patients compared to controls. Furthermore, compared to controls the PD patients had significantly more PPN cholinergic neurons containing mtDNA deletion levels exceeding 60%, a level associated with deleterious effects on oxidative phosphorylation. The current results differ from studies reporting mtDNA depletion in nigral dopaminergic neurons of PD patients. ANN NEUROL 2017; 82:1016 -1021 P arkinson disease (PD) patients typically present with tremor, bradykinesia, and rigidity, the onset and progression of which associate with selective loss of nigrostriatal dopaminergic neurons. 1 Interest has grown as to the role of nondopaminergic neurotransmission in PD. Cholinergic degeneration, affecting the basal forebrain, the nucleus basalis of Meynert, and a rostral brainstem structure called the pedunculopontine nucleus (PPN), associates with the onset and development of "axial" signs and cognitive impairment seen in PD patients. [2] [3] [4] Surviving (but susceptible) cholinergic neurons in these nuclei contain aggregated a-synuclein fibrils, forming Lewy bodies and Lewy neurites, a neuropathological hallmark of PD. 3 The links between mitochondria and PD pathoetiology are well studied. 5 This commenced in the 1980s, when the potent respiratory chain inhibitor 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, serving as a prodrug to the neurotoxin MPP1, was shown to cause parkinsonism in illicit drug users, 6 through to identification of complex-I-mediated reactive oxygen species forming within PD brains, 7 and continuing with inherited and somatic mitochondrial DNA (mtDNA) variants that were shown to affect PD risk. [8] [9] [10] Additionally, changes in mitochondrial DNA copy number (mtCN) were shown to associate with PD pathology, with vulnerable dopaminergic neurons showing depleted levels of wildtype mtCN.
11,12
Recently, we showed that several mitochondrial respiratory chain proteins are significantly upregulated in c-aminobutyric acidergic and glycinergic PPN neurons from PD postmortem brains. 3 Conversely, in the same patients, there was a marked reduction of these mitochondrial proteins in the cholinergic neurons of the PPN, suggesting mitochondrial injury. Moreover, we observed a significant reduction in mitochondrial mass across all 3 neuronal types, with the most pronounced loss seen in PPN cholinergic neurons. 3 Given the links between PPN cholinergic neuronal deterioration, mitochondrial function, and the development of PD, we investigated the role of mtDNA maintenance and stability in cholinergic neurons from the PPN of PD patients and controls.
Materials and Methods

Subjects
Postmortem human brains (n 5 6 controls, n 5 6 PD, male:female ratio 
PPN Identification
Serial sections (20 lm) were cut from the left hemisphere of PPN-containing brain blocks, using a cryostat (Bright Instrument Company, Luton, UK). To distinguish the PPN, pairs of sections (first and last in series) for each case were stained with hematoxylin and eosin ( Fig 1A) and Luxol fast blue (see Fig  1B) , using standard protocols. Paired stained sections were then used to define the PPN's boundaries, noting neighboring neural structures, including the lateral lemniscus, medial lemniscus, and superior cerebellar decussation. 13 
Single Cell Isolation
To immunohistochemically stain cholinergic neurons in PPNcontaining brain tissue sections, the sections were air-dried for 30 minutes at room temperature (RT) and then fixed for 20 minutes in 4% paraformaldehyde dissolved in phosphatebuffered saline (PBS). The sections were washed with PBS before blocking with 5% normal rabbit serum (S-5000; Vector Laboratories, Peterborough, UK) for 30 minutes, then incubated for 2 hours at RT with a primary antibody detecting choline acetyltransferase (polyclonal goat, 1:150; AB 144P; Millipore, Billerica, MA). After further washing in PBS, the secondary antibody (peroxidase horse antigoat, 1:200; PI-9500; Vector Laboratories) was applied for 1 hour at RT. Following washes in PBS, 3,3 0 ,5,5 0 -tetramethylbenzidine stabilized chromogen (Thermo Fisher, Paisley, UK), a substrate of horseradish peroxidase that oxides to form a blue chromogen, was applied to the sections for 10 minutes at RT and then rinsed well with distilled water. All antibody and serum dilutions were made using Tris-buffered saline. Individual PPN cholinergic neurons were isolated using the P.A.L.M. MicroBeam Laser-Capture Microdissection system coupled to an inverted Zeiss microscope (Axiovert 200M; Carl Zeiss, Oberkochen, Germany), and individually placed into adhesive cap microfuge tubes (Carl Zeiss) containing lysis buffer consisting of 50mM Tris-hydrochloride with 1% Tween 20 (pH 8.0) and 20mg/ml proteinase K (Thermo Fisher, Paisley, UK). Each lysis was immediately centrifuged at 13,000 revolutions/min and subsequently incubated at 558C for 16 hours, followed by incubation at 958C for 10 minutes. In total, 144 neurons were isolated (n 5 72 controls; n 5 72 PD).
mtDNA Analysis
Quantification of mtDNA was performed as previously described, 14 via a probe-based 11 multiplex Taqman quantitative polymerase chain reaction (PCR) to amplify the mitochondrial genes MTND1 and MTND4. mtCN was calculated by absolute quantification of MTND1, using the standard curve method, with serial dilutions of PCR-generated templates. PD and control samples (assayed in triplicate) were randomly assigned to each run to limit run-specific stratification.
Statistical Analysis
Data were analyzed using SPSS (version 22; IBM, Armonk, NY) with data-appropriate tests (detailed in text). Statistical significance was set at p < 5 3 10
22
. The choice of which analyses to apply was based on the data type. A correlative analysis was used when 2 continuous variables were present, for example, mtCN and PMI. A 1-way analysis of variance (ANOVA) was used where there were >2 categories whose means were to be compared, that is, mtCN versus Braak stage (stages 0-4). Data are expressed as the mean 6 SEM. The raw mtCN data are available on request.
Results
Comparison of mtDNA levels from single PPN cholinergic neurons showed a significant increase in mtCN in PD cases compared to controls (p 5 2.9 3 10 22 , 2-way ANOVA, PD mean 5 10,706 6 1,441 vs control mean 5 7,017 6 825; Fig 2A) . Importantly, no correlation was found between PMI and mtCN in either PD cases or controls (p 5
21
, respectively, linear regression analysis). Furthermore, no significant association was detected between mtCN and PD duration (p 5 9.7 3 10 21 , linear regression analysis) or between mtCN and Braak stage (p 5 3.1 3 10
, 1-way ANOVA; see Fig 2B) .
mtDNA deletion levels were also significantly increased in PD cases compared to controls (p 5 2.5 3 10 22 , 2-way ANOVA, PD mean 5 21.60 6 3.04% vs control mean 5 17.15 6 1.99%; see Fig 2C) . Again, no correlation was found between PMI and mtDNA deletions in either cases or controls (p 5
, respectively, linear regression analysis). However, mtDNA deletion levels correlated with higher Braak staging in PD patients (p 5 3 3 10 23 , 1-way ANOVA; see Fig 2D) . Stratification of individual neurons into high (ie, > 60%, at which level they are likely to exhibit a pathological phenotype 8 and lower mtDNA deletion levels (ie, < 60%, and therefore less likely to exhibit a pathological phenotype) revealed that PD cases harbored a disproportionately higher number of PPN cholinergic neurons with high mtDNA deletion load compared to controls (p < 1 3 10
24
, Fisher exact test; Fig 3A) .
Thus, unlike recent studies performed on substantia nigra pars compacta (SNpc) dopaminergic neurons taken from postmortem PD brains, and which reported mtCN depletion, 6,9,10,12 the current findings relating to single PPN cholinergic neurons showed significantly elevated mtCN and mtDNA deletion levels in PD patients compared to controls. We investigated this relationship further by using linear regression analysis. A significant negative correlation was observed between mtCN and mtDNA deletion levels in neurons taken from controls (r 5 22.5 3 10 21 , p 5 4.9 3 10 22 ), this finding resulting from very few neurons having higher levels of mtDNA deletions. When all data points from the PD brains were included, no significant association was detected between deletion levels and mtCN (r 5 5.4 3 10
22
, p 5 6.7 3 10 21 ; see Fig 3A) . An elevation in mtCN in response to the accumulation of mtDNA deletions might be considered evidence for cells' ability to proliferate mtDNA to maintain a critical number of wild-type mtDNA molecules to support a variety of physiological processes. This regression analysis was repeated by excluding neurons containing lower deletion levels (30%), as at these lower levels the neuroprotective processes might not have been triggered yet, thereby inhibiting the ability to detect a correlation between the 2 variables. The exclusion of neurons with lower mtDNA deletion levels did not reveal a significant relationship between deletion levels and mtCN (r 5
21
; see Fig 3B) . Taken together, our study reveals an elevation of mtCN and mtDNA deletion levels in PD patients compared to controls; however, a correlation was not detected between mtCN and mtDNA deletion levels in the single cholinergic neurons of the PD patients.
Discussion
This is the only study to date that characterizes mtCN and mtDNA deletion levels in cholinergic neurons of the PPN, a neuronal population that is highly vulnerable to cell death in PD patients. The aim was to better understand the role that mtDNA changes play in the loss of PPN cholinergic neurons in PD, which has been shown to be pivotal in the onset and progression of motor and nonmotor PD symptoms. Our investigations revealed that in remaining PPN cholinergic neurons of PD patients, mtCN is increased compared to controls. This is in contrast to studies that reported decreased mtCN levels within remaining SNpc dopaminergic neurons in PD postmortem brains, 8, 11, 12, 15 suggesting neuronal type-specific and brain region-specific responses to accumulation of mtDNA mutations in PD patients. However, similar to previous studies performed on SNpc dopaminergic neurons, 8, 11, 12, 15 our data indicate that mtDNA deletions are increased in PD patients compared to controls. Importantly, we show that in PD patients there is a substantial increase in the number of PPN cholinergic neurons containing >60% mtDNA deletion levels, making it highly likely that these neurons should manifest a respiratory chain deficiency. 8 Our data show that cholinergic neurons in the PPN, in contrast to reports of depletion in the SNpc of PD cases, 8, 11, 12, 15 appear to increase their mtCN in response to rising deletion levels. This raises the hypothesis that the PPN has a compensatory mechanism designed to maintain a pool of wild-type mtDNA molecules that is not present in the SNpc, or alternatively that the dopaminergic neurons of the SNpc are more vulnerable to rising mtDNA deletion levels than the cholinergic neurons of the PPN. The former appears to be supported by our data, as we detected a seemingly overall elevation in mtCN in the PD patients who also had higher deletion levels (see Fig 2A,  B) . This may reflect an inability by PPN cholinergic neurons to maintain the required level of wild-type mtDNA past this threshold deletion level, or might result from the smaller number of neurons with high levels of mtDNA deletions that we observed here. Nevertheless, this exploratory observation should be explored further in future studies.
Although not a conclusive indicator of PD, Braak staging indicates disease advancement. 16 In this study, we identified a significant difference between high mtDNA deletion levels and advanced Braak staging, supporting the hypothesis that mtDNA deletions within PPN cholinergic neurons contribute to PD progression. This is similar to SNpc dopaminergic neurons in PD patients, where Lewy body abundance, associated with advanced Braak staging, coincided with increased mtCN, which was hypothesized as a possible compensatory response against deficient levels of adenosine triphosphate. 17 In the current study, we found no significant difference in PPN cholinergic neuronal mtCN values between the different Braak stages; however, this is an area that merits additional investigation in future studies.
In conclusion, we show increased mtCN and mtDNA deletion levels within remaining PPN cholinergic neurons in PD patients compared to controls. We further found significantly more cholinergic neurons harboring mtDNA deletion levels that associate with a mitochondrial dysfunction in PD, compared to controls. These findings support the view that mtDNA deletions are frequent in PPN cholinergic neurons and that these might play a role in the death of these neurons in PD patients. Critically, the data suggest that different brain regions and neurochemical cell types vary in their responses to accumulated mtDNA deletions in PD patients, because the data contrast with prior observations relating to SNpc dopaminergic neurons.
